Multiple Myeloma Research at ASH23: Dana-Farber's Paul Richardson, MD, discusses the results of the MEZI trial, which show promising efficacy results in treating relapsed/refractory multiple myeloma.
What we were pleased to see and what we reported was that the combination of me ziggy, which is a potent uh oral uh cerebro E three ligase modulator or so called cell mod. What we were able to see that in immunomodulator, refractory and pre proteome inhibitor refractory as well as heavily pretreated patients, striking response rates in excess of 80%. And what we were also able to see is that various schedules of our drug were particularly effective. We also looked able to look at different dosing to best understand the interaction in terms of um the effects on uh the degradation of icaro and ALOS, which were a key part of our study. And at the same time, some of the cellular components of the effects that these important agents have specifically on T cells. So in the context of the auma combination approach, we were able to show that again, this response in general, over 80% manageable safety profile, which is very encouraging and remarkably in our most mature cohort of patients, we have duration of responses succeeding three years. And we have patients who are now 41 and 42 months into their treatment with very high quality responses. VG PR and CRC. So really from a relapse refractory patients perspective, a simple oral therapy with a monthly injection of antibody provides a really promising platform going forward. Now in our elotuzumab cohort of patients, here, we combine the ziggy with tuum with the rationale that we would impact favorably on natural killer cell activity. And our correlative science suggested that was the case. Importantly, we were able here to treat patients who are not only refractory uh to immunomodulatory treatments and proteome inhibitors, but were also refractory to CV 38 mono antibodies. And when we did this, we were able to show a very respectable response rate around 45%. And with durability seen recognizing this is a distinct subgroup of patients different to the dra tumor cohort where we've seen such remarkable results. What we were also very pleased to see with the tuum based combination was excellent tolerability. So all of this amounts to I think a very promising start for Azy amide as a combination treatment with other immune therapies. I think it informs us in terms not only of the laum and dab in particular, but also the promise of combining this when we think about targeting BC MA for example and for that matter G PR C five D. So a very exciting set of results
